MANNKIND CORP Interest Income, Debt Securities, Held-to-maturity
MANNKIND CORP (MNKD) reported Interest Income, Debt Securities, Held-to-maturity of $3.20 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity · last filed 2024-11-07
- MANNKIND CORP interest income, debt securities, held-to-maturity for the quarter ending 2024-09-30 was $3.20M, a 113.33% increase year-over-year.
- MANNKIND CORP interest income, debt securities, held-to-maturity for the quarter ending 2024-06-30 was $3.20M, a 128.57% increase year-over-year.
- MANNKIND CORP interest income, debt securities, held-to-maturity for the quarter ending 2023-09-30 was $1.50M, a 114.29% increase year-over-year.
- MANNKIND CORP interest income, debt securities, held-to-maturity for the quarter ending 2023-06-30 was $1.40M, a 180.00% increase year-over-year.
| Period end | Interest Income, Debt Securities, Held-to-maturity 3 month | Interest Income, Debt Securities, Held-to-maturity 3 month as first filed | Interest Income, Debt Securities, Held-to-maturity 6 month | Interest Income, Debt Securities, Held-to-maturity 6 month as first filed | Interest Income, Debt Securities, Held-to-maturity 9 month | Interest Income, Debt Securities, Held-to-maturity 9 month as first filed |
|---|---|---|---|---|---|---|
| 2024-09-30 | $3.20M 10-Q · filed 2024-11-07 | $6.40M derived: sum of 2 quarters · filed 2024-11-07 | $9.80M 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $3.20M 10-Q · filed 2024-08-07 | $6.60M 10-Q · filed 2024-08-07 | ||||
| 2023-09-30 | $1.50M 10-Q · filed 2024-11-07 | $1.00M 10-Q · filed 2023-11-07 | $2.90M derived: sum of 2 quarters · filed 2024-11-07 | $4.00M 10-Q · filed 2024-11-07 | $3.20M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $1.40M 10-Q · filed 2024-08-07 | $1.00M 10-Q · filed 2023-08-07 | $2.60M 10-Q · filed 2024-08-07 | $2.20M 10-Q · filed 2023-08-07 | ||
| 2023-03-31 | $1.20M 10-Q · filed 2023-05-09 | |||||
| 2022-09-30 | $700.00K 10-Q · filed 2023-11-07 | $1.20M derived: sum of 2 quarters · filed 2023-11-07 | $1.60M 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | $500.00K 10-Q · filed 2023-08-07 | $900.00K 10-Q · filed 2023-08-07 | ||||
| 2022-03-31 | $400.00K 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |